A Review on Febuxostat as Uric Acid Lowering Agent

Abstract

Febuxostat is a novel, potent and non-purine selective xanthine oxidase inhibitor which got approved for market in the year 2011by central drug standard control organisation (CDSCO), in India under the brand name febutaz. Febuxostat is initially developed as xanthiene oxidase inhibitor to treat hyperuricemia in gout patients, has evolved into a versatile therapeutic agent with multifecated applications. It has been shown to be effective in reducing serum uric acid levels, preventing gout attacks, and improving quality of life. Febuxostat unique mechanism of action, pharmacokinetic profile, and clinical efficacy make it a valuble to alternative to traditional uric acid lowering agent like allopurinol. Febuxostat is particularly usefull  in patients with kidney disease ,where allopurinol is limited .overall this review provides a comphrensive overview of febuxostat mechanism of action ,its effectiveness in gout management ,its cardiovascular safety profile, renal and hepatic effects ,safety considerations and emerging research prospects. Its once daily dosing and lack of food interactions further enhances its clinical utility. Overall, febuxostat represents a significant advancement in the management of hyperuricemia and gout, offering a safe and effective treatment option for patients.